0HNZ Stock Overview
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
Fagron NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €17.48 |
52 Week High | €18.36 |
52 Week Low | €14.65 |
Beta | 0.28 |
1 Month Change | 2.25% |
3 Month Change | 3.49% |
1 Year Change | -0.032% |
3 Year Change | -5.20% |
5 Year Change | 5.24% |
Change since IPO | 74.80% |
Recent News & Updates
Recent updates
Shareholder Returns
0HNZ | GB Healthcare | GB Market | |
---|---|---|---|
7D | 2.7% | 1.2% | 0.4% |
1Y | -0.03% | -27.5% | -1.0% |
Return vs Industry: 0HNZ exceeded the UK Healthcare industry which returned -27.5% over the past year.
Return vs Market: 0HNZ matched the UK Market which returned -1% over the past year.
Price Volatility
0HNZ volatility | |
---|---|
0HNZ Average Weekly Movement | 2.4% |
Healthcare Industry Average Movement | 7.5% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HNZ has not had significant price volatility in the past 3 months.
Volatility Over Time: 0HNZ's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 3,282 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.
Fagron NV Fundamentals Summary
0HNZ fundamental statistics | |
---|---|
Market cap | €1.30b |
Earnings (TTM) | €70.55m |
Revenue (TTM) | €762.99m |
18.4x
P/E Ratio1.7x
P/S RatioIs 0HNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0HNZ income statement (TTM) | |
---|---|
Revenue | €762.99m |
Cost of Revenue | €430.38m |
Gross Profit | €332.61m |
Other Expenses | €262.07m |
Earnings | €70.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 01, 2024
Earnings per share (EPS) | 0.97 |
Gross Margin | 43.59% |
Net Profit Margin | 9.25% |
Debt/Equity Ratio | 69.7% |
How did 0HNZ perform over the long term?
See historical performance and comparison